Cellinfinity Bio

At Cellinfinity, we believe cells have infinite potential to cure human diseases. We have used our proprietary directed evolution platform to identify set of gene modifications that substantially improve CAR-T and CAR-NK cells to cure solid tumors. Our directed evolution process involves site-specific knock-in of CRISPR guide library and allows whole genome gain-of-function or loss-of-function evaluation. Following selection of engineered cells with desired properties (e.g. potency, proliferation, infiltration and in vivo activity against solid tumors) we identified set of unique gene modifications in CAR-Ts and CAR-NKs that substantially augment anti-tumor activity. We have used this technology to develop first-in-class and/or best-in-class portfolio products (CAR-Ts and CAR-NKs) armored with specific gene enhancements against solid tumors.